Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Regeneron Pharmaceuticals, Inc.

More than two dozen At Home stores are set to close by the end of September as the company continues to deal with dwindling sales and crippling debt.

Officials for retailer Claire's filed for bankruptcy protection on Wednesday as its operating costs rise while demand for its ...

Following the sale of the direct-to-consumer genetic testing company 23andMe, the Utah Attorney General’s Office is issuing a ...

Regeneron Pharmaceuticals is conducting a clinical study titled ‘A Single-Arm, Open-Label, Safety Study in Patients With Generalized Lipodystrophy Switching From Metreleptin to Mibavademab, A ...

Following the sale of the direct-to-consumer genetic testing company 23andMe, the Utah Attorney General’s Office is issuing a consumer advisory reminding former customers of ways to protect ...

Related video: Utah experts weigh in on sensitivity of DNA data after 23andMe files for bankruptcy SALT LAKE CITY (ABC4) — A bankruptcy court has approved the sale of all of 23andMe ‘s assets, ...

Tobacco giant Altria beat Wall Street estimates for second-quarter revenue and profit on Wednesday, helped by strong demand for its on! nicotine pouches.

Bar K, a dog bar chain, said on Tuesday, July 29 it is closing all three of its locations in St. Louis, Kansas City and Oklahoma City.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the most profitable biotech stocks to invest in now. Canaccord updated estimates on Regeneron Pharmaceuticals, Inc.

Regeneron Gets a Boost: Asset Management One Invests Snack-Sized Version: Asset Management One Co. Ltd. has increased its stake in Regeneron Pharmaceuticals, Inc. by 6.2% in the fourth quarter, now ...

Investors will focus on profits from asthma drug Dupixent and sales of Eylea HD when biotech giant Regeneron Pharmaceuticals, Inc. (REGN) reports second-quarter 2025 results on Aug. 1, 2025.